Last reviewed · How we verify

Increlex — Competitive Intelligence Brief

Increlex (MECASERMIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Insulin-like growth factor 1 receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Increlex (MECASERMIN) — Ipsen Inc. Increlex works by mimicking the action of insulin-like growth factor 1 (IGF-1) to stimulate growth in individuals with Laron syndrome.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Increlex TARGET MECASERMIN Ipsen Inc marketed Insulin-like growth factor 1 receptor 2005-01-01
TEPEZZA TEPROTUMUMAB-TRBW HORIZON THERAPEUTICS IRELAND marketed Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] Insulin-like growth factor 1 receptor
Increlex Increlex Children's Hospital Medical Center, Cincinnati marketed Insulin receptor, Insulin-like growth factor 1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Increlex — Competitive Intelligence Brief. https://druglandscape.com/ci/mecasermin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: